Tag: Teva
-
Teva’s Weltruza Wins FDA Approval for Monthly Schizophrenia Treatment
Teva’s Weltruza wins FDA approval for monthly schizophrenia treatment. Medincell’s delivery technology reduces administration burden, while olanzapine’s metabolic risks remain.
-
Teva’s TEV-‘408 Meets Phase 2a Primary Endpoint in Celiac Disease by Reducing Gluten-Induced Intestinal Damage
Teva’s anti-IL-15 antibody TEV-‘408 met the primary endpoint in a Phase 2a celiac disease study, significantly reducing gluten-induced intestinal damage and limiting intraepithelial lymphocyte expansion versus placebo.